Literature DB >> 2844083

Pharmacokinetics of lisinopril.

B Beermann1.   

Abstract

The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food. The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours. Steady state is attained after two daily doses (every 24 hours) in healthy volunteers. The drug is not metabolized but is eliminated via the kidneys. Lisinopril probably undergoes glomerular filtration, tubular secretion, and tubular reabsorption. There is no pharmacokinetic interaction between lisinopril and furosemide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844083     DOI: 10.1016/0002-9343(88)90346-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

2.  Massive Atenolol, Lisinopril, and Chlorthalidone Overdose Treated with Endoscopic Decontamination, Hemodialysis, Impella Percutaneous Left Ventricular Assist Device, and ECMO.

Authors:  C William Heise; David Beutler; Adam Bosak; Geoffrey Orme; Akil Loli; Kimberlie Graeme
Journal:  J Med Toxicol       Date:  2015-03

Review 3.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

4.  Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Authors:  Felix Stader; Hannah Kinvig; Melissa A Penny; Manuel Battegay; Marco Siccardi; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

Review 5.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 6.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 7.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 8.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  Magnetic resonance imaging catheter stress haemodynamics post-Fontan in hypoplastic left heart syndrome.

Authors:  Kuberan Pushparajah; James K Wong; Hannah R Bellsham-Revell; Tarique Hussain; Israel Valverde; Aaron Bell; Aphrodite Tzifa; Gerald Greil; John M Simpson; Shelby Kutty; Reza Razavi
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-07-18       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.